ITCI vs. VKTX, JAZZ, CYTK, CERE, ELAN, IONS, ASND, APLS, LEGN, and BPMC
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Viking Therapeutics received 94 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 67.34% of users gave Intra-Cellular Therapies an outperform vote.
In the previous week, Viking Therapeutics had 2 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 21 mentions for Viking Therapeutics and 19 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.71 beat Viking Therapeutics' score of 0.57 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics has higher earnings, but lower revenue than Intra-Cellular Therapies. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics presently has a consensus target price of $112.25, indicating a potential upside of 63.01%. Intra-Cellular Therapies has a consensus target price of $90.17, indicating a potential upside of 25.01%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Intra-Cellular Therapies.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -30.08%. Viking Therapeutics' return on equity of -23.02% beat Intra-Cellular Therapies' return on equity.
Viking Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
Summary
Viking Therapeutics beats Intra-Cellular Therapies on 12 of the 17 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
